A study in the New England Journal of Medicine found that the Eli Lilly and Co. glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide demonstrated a positive effect in patients with metabolic dysfunction-associated steatohepatitis and fibrosis. The diabetes and weight loss drug was also associated with improvements in markers of liver health.
Full Story: MedPage Today (free registration) (6/8)